Brodalumab: Six-Year US Pharmacovigilance Report

Brodalumab: Six-Year US Pharmacovigilance Report

Abstract Introduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies....

Full description

Saved in:
Bibliographic Details
Main Authors: Mark G. Lebwohl, John Y. Koo, April W. Armstrong, Bruce E. Strober, Soo Han Yoon, Nicole N. Rawnsley, Earl L. Goehring, Gina D. Mangin, Abby A. Jacobson
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-11-01
Series:Dermatology and Therapy
Subjects:
Adverse events
Drug reaction
Psoriasis
Real-world
Safety
Online Access:https://doi.org/10.1007/s13555-024-01304-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-024-01304-y

Similar Items